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A  65-year-old  woman  underwent  coronary  artery  bypass  surgery  and  was  diagnosed  with  antiphospho-
lipid  syndrome  (APS)  at  the same  time  in  1985.  She  was  admitted  to our  hospital  to undergo  mastectomy
for  left  breast  cancer  in  2012.  She  was  put  on  intravenous  infusion  of heparin  and stopped  receiving  both
antiplatelet  agents  and  warfarin.  The  operation  was  performed  without  complications,  and  antithrom-
botic  therapy  was  restarted  one  day  after  the  operation.  On  day  6 postoperative,  she  complained  of  suddencute myocardial infarction
ntiphospholipid syndrome
oronary  artery bypass surgery
erioperative management
ntithrombotic therapy
chest  pain  and  on  examination  she  was  diagnosed  with  acute  myocardial  infarction.  The  culprit  lesion
was  in a saphenous  vein  graft and  coronary  intervention  was  performed.
<Learning objective:  Antithrombotic  therapy  for patients  with  APS  is complicated  because  of  prolonged
baseline  activated  partial  thromboplastin  time  (aPTT).  An  effective  perioperative  antithrombotic  therapy
for  APS  patients  who  have  a history  of  coronary  artery  disease  and  have  undergone  non-cardiac  surgery
has  not  yet  been  established.  A safe  strategy  for such  a therapy  should  therefore  be  discussed.>
© 2014  Japanese  College  of Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.ntroduction
Antiphospholipid syndrome (APS) increases the risk of coronary
rtery disease [1,2]. Perioperative management of antithrombotic
herapy for patients with APS is complicated because of prolonged
aseline activated partial thromboplastin time (aPTT). We  report
ere a case of an APS patient with a history of coronary artery bypass
urgery suffering acute myocardial infarction during perioperative
eriod of non-cardiac surgery.
ase report
A 65-year-old woman underwent coronary artery bypass
urgery (– ascending aorta – saphenous vein graft – left anterior
escending artery –) because of left main trunk stenosis and was
iagnosed with APS at the same time in 1985. Prior to the surgery,
he had been diagnosed with diabetes and deep venous thrombo-
is and had been receiving antithrombotic therapy with warfarin,
spirin and ticlopidine.
∗ Corresponding author. Tel.: +81 024 534 6101; fax: +81 024 534 5205.
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878-5409/$ – see front matter © 2014 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jccase.2014.01.008She was admitted to our hospital to undergo mastectomy for
left breast cancer in September 2012. Laboratory data showed a
prolonged aPTT of 79.5 s (reference 23.0–38.0 s). She was put on
intravenous heparin infusion of about 10,000 units per day and
stopped receiving warfarin, aspirin, and ticlopidine 7 days before
the operation. The infusion of heparin was adjusted to keep the
aPTT at approximately 100 s and was  stopped 6 h before the oper-
ation. Warfarin, aspirin and ticlopidine were restarted 1 day after
the operation. She received the infusion of heparin on days 1 and
2 after the operation. Six days after operation she complained of
sudden chest pain and her electrocardiogram revealed ST-segment
elevation in I, aVR, aVL, and V4–6 leads. She was  then diagnosed
with acute myocardial infarction. The PT-INR and aPTT of 6 days
after the operation were 1.24 and 61.6, respectively. Emergent
cardiac catheterization was performed. A 99% stenosis with delay
was detected in the saphenous vein graft and a 90% stenosis was
detected in the left anterior descending artery (Fig. 1). Under the
support of intraaortic balloon pumping, percutaneous intervention
was performed on the culprit lesion in the saphenous vein graft
with a bare metal stent and plain old balloon angioplasty to the
left anterior descending artery. The patient’s maximum creatinine
kinase was 7522 IU/L, and the presence of heart failure was deter-
mined. She was stabilized by intensive care and had no recurrence
vier Ltd. All rights reserved.
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as  performed in the saphenous vein graft. (c) Final angiography showed TIMI grad
f any thromboembolic diseases or bleeding complications. About
 months after the onset of acute myocardial infarction she was
ransferred to a different hospital for rehabilitation.
iscussion
The prevalence of antiphospholipid antibodies is about 1–4% in
ormal controls [3]. Our patient did not have systemic lupus erythe-
atosus, although about 11–38% of patients with systemic lupus
rythematosus have antiphospholipid antibodies [3,4]. The preva-
ence rates of myocardial infarction, angina pectoris, and coronary
ypass rethrombosis in patients with APS are 5.5%, 2.7%, and 1.1%,
able 1
ntithrombotic strategies during perioperative period of cardiac surgery.
Patient Preoperative
anticoagulation
Intraoperative
anticoagulation with
heparin
Baseline
aPTT  (s)
Basel
(s)
69-year-old man
(redo  CABG)
None  ACT 48.7 None
44-year-old man
(MVR)
None  Double the baseline ACT 49.8 430 
47-year-old man
(CABG)
None  Heparin concentration 47 236 
51-year-old man
(CABG  + MVR)
None  (1) Celite ACT
(2)  Anti-Xa concentration
52 None
49-year-old
woman (MVR)
None (1) Celite ACT
(2)  Anti-Xa concentration
45.8 None
25-year-old
woman (AVR)
None Heparin concentration 68 249 (
192 (
46-year-old
woman (MVR)
None Heparin concentration 116 219 
33-year-old
woman (MVR)
Enoxaparin
100 mg/day
(1) Kaolin ACT
(2)  Anti-Xa concentration
44.5 147 
31-year-old
woman (MVR)
i.v. heparin to
double  the
baseline aPTT
(1) Kaolin ACT greater than
600 s
(2)  Anti-Xa concentration
49 168 
40-year-old man
(OPCAB)
None  (1) Celite ACT greater than
300  s
(2)  Heparin concentration
61.8 112 
33-year-old man
(MVP)
Enoxaparin  Celite ACT greater than
500 s
42 153 
68-year-old man
(OPCAB)
None  (1) ACT
(2) Heparin concentration
60.4 228 
70-year-old man
(CABG  + AVR)
None  (1) Celite ACT
(2)  Heparin concentration
(3)  Anti-Xa concentration
65 123 (
Over
(kaol
PTT, activated partial thromboplastin time; ACT, activated coagulation time; CABG, co
ulmonary thromboembolism; MVR, mitral valve replacement; AVR, aortic valve replacehenous vein graft. (b) Coronary intervention with a bare metal stent (white arrows)
ow. White arrows show the location of the bare metal stent.
respectively  [1]. Because of APS, our patient had a history of cardio-
vascular disease when she was young, and experienced recurrent
cardiovascular events. The risk of such recurrent cardiovascular
events is high in post-infarction patients with antiphospholipid
antibodies [2,3]. We  should be careful of cardiovascular events in
patients with APS, especially those who have a history of coronary
artery disease.
Diabetes, cancer, as well as surgery are risk factors of thrombosis
[2], and were related to recurrent myocardial infarction in our case.
Furthermore, antiphospholipid antibodies are associated with graft
failure [5,6]. Safe preoperative management for patients with APS
is important to prevent this.
ine ACT Actual ACT (s) Complications Report
 540–660 Bleeding, renal
failure,  DVT, s/o PTE,
ischemia  of the toes
Sheikh  et al. [13]
Over 999 None Sheikh et al. [13]
Over 999 None Ducart et al. [14]
 Over 550 Bleeding East et al. [15]
 Over None East et al. [15]
kaolin)
celite)
Over 999
(kaolin)
Over 1500
(celite)
Bleeding  Hogan et al. [16]
Over 999 Cardiac tamponade
rhythm disturbances
Brownstein et al. [10]
388–517 None Lennon et al. [11]
603–819 Acute biventricular
failure
Dorman [17]
300 None Maddali and Albahrani [12]
417–601 None Weiss et al. [18]
764–945 Arteriovenous ﬁstula
thrombus,  atrial
ﬁbrillation
Jervis et al. [19]
celite)
 200
in)
Over 600
(celite)
Over 999
(kaolin)
None  Cartwright et al. [20]
ronary artery bypass grafting; DVT, deep vein thrombosis; s/o, suspected of; PTE,
ment; OPCAB, off-pump coronary artery bypass.
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ACCF/AHA focused update on perioperative beta blockade incorporated into the
ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and careT. Yokokawa et al. / Journal of 
There are only a few reports of perioperative antithrombotic
herapies for patients with APS. We  chose here unfractionated
eparin therapy as a bridging therapy instead of warfarin, aspirin
nd ticlopidine. Management of heparin therapy in patients with
PS is complicated because of prolonged baseline aPTT. In our
ase, aPTT was within therapeutic range determined by aPTT
atios of approximately 2.5 times the reference value [7] but
yocardial infarction happened. The bridging therapy was  an
mportant factor of acute myocardial infarction due to saphenous
ein graft failure 28 years after coronary artery bypass surgery.
revious reports suggested the possibility of underanticoagulation
nd recommended the use of unfractionated heparin or low
olecular weight heparin [8,9]. Some reports show preoperative
ntithrombotic therapy using enoxaparin or heparin with doubling
he baseline aPTT in cardiac surgery for patients with APS [10–12].
ntraoperative antithrombotic therapies by heparin have been
eported to double the baseline activated coagulation time, to
onitor anti-Xa concentration, and heparin concentration in
ardiac surgery for patients with APS ([10–20], Table 1). However,
he strategy of antithrombotic therapy during perioperative period
f non-cardiac surgery for patients with APS has not been docu-
ented in literature. We  propose that the strategy of perioperative
ntithrombotic therapy for cardiac surgery in APS patients should
pply to the patients undergoing non-cardiac operation. It is worth
sing unfractionated heparin with doubling the baseline aPTT or
sing low molecular weight heparin.
Early discontinuation of heparin before enough blood concen-
ration of warfarin might be one of possible reasons of myocardial
nfarction in this case. We  should have used heparin until achiev-
ng therapeutic range of substitute antithrombotic medication like
arfarin.
Some reports described perioperative management of patients
ith coronary artery disease during non-cardiac surgery. Using
itrate or nicorandil may  be another option to reduce the risk of
ardiovascular disease during perioperative period [21,22].
A  safe strategy should be established regarding perioperative
ntithrombotic therapy for patients with APS and a history of coro-
ary artery disease.
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